Clinical trials: Dalteparin
Thrombosis, Venous
Hemorrhage Risk Prescribed Arixtra
Arixtra (fondaparinux sodium) was the first selective Factor Xa inhibitor to be marketed. As with all anticoagulants, an important adverse event associated with Arixtra use is haemorrhage.
- Trial name
- NCT01064362
- Testing
- Fondaparinux sodium, Low molecular weight heparin (LMWH)
- Volunteers
- 13,442 people
- Sponsor
- GlaxoSmithKline
Deep Venous Thrombosis, Pulmonary Embolism
Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
This is a randomized-controlled open-label trial comparing two different doses of low-molecular-weight heparin (LMWH) in pregnant patients with a history of previous venous thromboembolism (VTE).
- Trial name
- Highlow (NCT01828697)
- Testing
- Low dose nadroparin, Intermediate dose nadroparin, Low dose enoxaparin
- Where
- 72 sites in United States, Belgium and 8 more
- Volunteers
- 1,110 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Venous Thromboembolism, Renal Impairment
Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function
This is a clinical trial including non-surgical patients, 70 years of age or older, with renal impairment requiring pharmacological venous thromboembolism prevention during hospitalization.
- Trial name
- NCT03158792
- Testing
- Enoxaparin 20Mg/0.2mL Prefilled Syringe, Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml
- Where
- Lebanon
- Volunteers
- 32 people
- Sponsor
- Lebanese American University
Venous Thromboembolism
Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis
The purpose of this study is to evaluate whether low-molecular-weight heparin could be equally or more effective than oral anticoagulation in the long-term treatment of deep venous thrombosis.
- Trial name
- NCT00689520
- Testing
- tinzaparin, acenocoumarol
- Where
- 2 sites in Spain
- Volunteers
- 241 people
- Sponsor
- Hospital Universitari de Bellvitge
Anti-Xa Assay in Pulmonary Embolism
Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism
The aim of the present study is to monitor anticoagulant therapy by anti-Xa assay and correlate its level to the efficacy and safety of enoxaparin in the treatment of pulmonary embolism.
- Trial name
- NCT02977013
- Testing
- Anti-Xa assay
- Volunteers
- 42 people
- Sponsor
- Mohamed Sayed Mohamed Abbas
Venous Thromboembolism, Cancer
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.
- Trial name
- NCT00981903
- Testing
- Tinzaparin sodium
- Where
- 2 sites in United States
- Volunteers
- 131 people
- Sponsor
- University of Southern California
Renal Failure, Hemodialysis
OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH) in Hemodialysis
A randomised, prospective, cross over study will be done to determine whether the anticoagulation therapy with UFH or LMWH used for hemodialysis sessions modifies osteoprotegerin and RANKL plasma levels.
- Trial name
- NCT00669721
- Testing
- law molecular weigth heparin, unfractioned heparin
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Habitual Abortion
Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion
1 % of all pregnancies end in habitual/recurrent abortion. In about half of women with habitual abortions (HAB) hereditary or acquired (antiphospholipid antibodies) thrombophilia are observed.
- Trial name
- HABENOX (NCT00959621)
- Testing
- Aspirin, Klexane, Klexane and ASA
- Where
- Finland
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of Helsinki
Drug Monitoring, Anticoagulants
Plasma Concentration Monitoring of Direct Oral Anticoagulants in Emergency Department Patients: Comparison of Two Laboratory Methods
The goal of this observational study is to learn whether two laboratory tests give the same results when measuring blood levels of blood thinners.
- Conditions
- Drug Monitoring, Anticoagulants, Factor Xa Inhibitors, Direct Oral Anticoagulants (DOACs)
- Trial name
- Plasma Concent (NCT07917455)
- Where
- 2 sites in Italy
- Volunteers
- 142 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Pregnancy, Prosthetic Heart Valve
Optimizing Anticoagulation in Pregnancies With Mechanical Heart Valves
The purpose of this pilot study is to collect data on pregnancies with mechanical heart valves to see if using a blood thinner called low molecular weight heparin (LMWH) and low dose aspirin (LDA) is comparable to…
- Conditions
- Pregnancy, Prosthetic Heart Valve, Anticoagulant Therapy
- Trial name
- NCT07658989
- Testing
- LMWH and LDA, Vitamin K antagonists (e.g warfarin)+/- LDA, Sequential therapy +/- LDA
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Mount Sinai Hospital, Canada
Postpartum Period, Cesarean Section Surgery
Rivaroxaban vs Enoxaparin After Cesarean Section: Laboratory Thromboprophylaxis Outcomes
Pregnancy and the postpartum period increase venous thromboembolism (VTE) risk. After cesarean section, low-molecular-weight heparin (LMWH; enoxaparin) is commonly used for short-term thromboprophylaxis, but it requires daily…
- Conditions
- Postpartum Period, Cesarean Section Surgery, VTE (Venous Thromboembolism)
- Trial name
- NCT07820670
- Testing
- Rivaroxaban, Enoxaparin 40 mg
- Where
- Israel
- Volunteers
- 62 people
- Sponsor
- Wolfson Medical Center
Antiphospholipid Syndrome in Pregnancy, Pregnancy Loss
AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study
The APPLE pilot trial is a feasibility study that is a multicentre, open-label, randomized controlled trial. Pregnant women with antiphospholipid syndrome (APS) and a history of late (≥10 weeks gestation) or recurrent early (2…
- Trial name
- APPLE (NCT03100123)
- Testing
- Aspirin 81 mg, Low-molecular-weight heparin
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Ottawa Hospital Research Institute
Non-Small Cell Lung Cancer
Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)
Rationale: a number of recent phase III randomized trials have shown a survival benefit of a treatment with subcutaneous low-molecular weight heparin in patients with advanced solid malignancies.
- Trial name
- SYRINGES (NCT00771563)
- Testing
- cisplatin + docetaxel, cisplatin + docetaxel + enoxaparin
- Where
- 2 sites in Belgium
- Volunteers
- 104 people
- Sponsor
- University Hospital, Antwerp
Venous Thromboembolism
Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany
Researcher in this study want to compare the effectiveness of Rivaroxaban (Xarelto) versus low-molecular-weight heparin (LMWH) and phenprocoumon for the treatment and secondary prevention of venous thromboembolism by evaluating…
- Trial name
- NCT04444804
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939), LMWH and Phenprocoumon
- Where
- Germany
- Volunteers
- 22,153 people
- Sponsor
- Bayer
Venous Thromboembolic Disease
Comparison of the 'CTR' Ratio With Standard Haemostasis Parameters in the Follow-up of Patients Undergoing Heparin Therapy
The Quantra(r) hemostasis analyzer (Stago) is a recent addition to the family of global hemostasis tests. It uses ultrasound-based technology to characterize the viscoelastic properties of a whole blood sample during coagulation.
- Trial name
- QuantiXa (NCT05993533)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
High Risk Pregnancy
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy
Anticoagulant therapy is indicated during pregnancy for the prevention and treatment of venous thromboembolism, systemic embolism in patients with mechanical heart valves and, in combination with aspirin, for the prevention of…
- Trial name
- NCT04110444
- Testing
- Sildenafil
- Where
- Egypt
- Volunteers
- healthy volunteers welcome
- Sponsor
- Fayoum University Hospital
Adenomyosis, Assisted Reproductive Technology
Low Molecular Weight Heparin on the Adenomyosis Patients'IVF-ET Outcome
In assisted reproductive technology, adenomyosis patients are characterized by lower clinical pregnancy rate, lower implantation rate and higher abortion rate.
- Trial name
- NCT04741295
- Testing
- Low molecular weight heparin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Nanjing University
Cancer, Thrombosis
Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients
The purpose of the study is to determine the Pharmacokinetics of Low Molecular Weight Heparin (LMWH) in Cancer patients, and compare it to the Pharmacokinetics of LMWH in Patients without cancer.
- Conditions
- Cancer, Thrombosis, Angina Pectoris
- Trial name
- NCT00716898
- Where
- Israel
- Volunteers
- 25 people
- Sponsor
- Shaare Zedek Medical Center
Atrial Fibrillation
Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as antithrombotic therapy for patients in atrial…
- Trial name
- NCT00289042
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The Cleveland Clinic